Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

123.54 +24.53 (+24.78%)
Official Closing Price Updated: 4:15 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Illumina Announces the Thirteenth Agricultural Greater Good Grant Winner
SOURCE: Illumina 
Via 3BL Media
Record-breaking Achievement at Rady Children's Institute for Genomic Medicine
SOURCE: Illumina 
Via 3BL Media
Has Illumina Lost Its Shine?
Cathie Wood lost her conviction and dumped the stock. Can Illumina get back on track? 
Via The Motley Fool
Topics Regulatory Compliance
DNA Data Storage Alliance Publishes First White Paper, Launches Website
From Twist Bioscience Corporation
Via Business Wire
Illumina Celebrates World Oceans Day
SOURCE: Illumina 
Via 3BL Media
Illumina Celebrates AAPI Heritage Month
SOURCE: Illumina 
Via 3BL Media
Asia Pacific Single-Cell Analysis Market – High Growth Potential of Single-Cell Sequencing
The Asia Pacific single-cell analysis market is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a CAGR of 20.1% 
Via SBWire
Unlocking the Covid Code
SOURCE: Illumina 
Via 3BL Media
Topics Earnings
San Diego Squared Is Empowering Tomorrow's STEM Leaders Today
SOURCE: Illumina 
Via 3BL Media
Bringing Bright Minds Together at SPARK
SOURCE: Illumina 
Via 3BL Media
Will Illumina Be a Trillion-Dollar Stock by 2035?
It'll cover a lot of ground in the next 14 years. 
Via The Motley Fool
Molecular Biology Enzymes and Kits & Reagents Market Worth $29.7 Billion by 2026 - Exclusive Report by MarketsandMarkets™
The global molecular biology enzymes market is projected to $29.7 billion by 2026. Molecular biology enzymes and kits & reagents market report provides crucial industry insights that will help your... 
Via SBWire
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
Illumina Recognized in Just Capital's Top 100 Companies Supporting Healthy Families & Communities
SOURCE: Illumina 
Via 3BL Media
Illumina and Microba Life Sciences Partner to Accelerate Microbiome Research
SOURCE: Illumina 
Via 3BL Media
This Biotech Just Made History. Will Its Stock Follow?
Twenty years after the human genome was sequenced, a new wave of discovery has begun. 
Via The Motley Fool
Expert Ratings for Illumina
Illumina (NASDAQ:ILMN) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 2 1 Somewhat... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2021
Upgrades For Equity Residential (NYSE:EQR), BMO Capital upgraded the previous rating of Market Perform to Outperform. Equity Residential earned $0.68 in the first quarter... 
Via Benzinga
Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
From Illumina, Inc.
Via Business Wire
Could Bionano Genomics Be a Millionaire-Maker Stock?
This provider of genome mapping tools is showing signs of exponential growth ahead. 
Via The Motley Fool
Illumina To Webcast Upcoming Investor Conference
From Illumina, Inc.
Via Business Wire
PCR- and NGS-Based Diagnostic Testing Market Revenue to Cross USD 26.5 Bn by 2027: Global Market Insights Inc.
Major PCR- and NGS-based diagnostic testing market players include Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Eppendorf AG; Fluotics; Hamilton Company; Illumina, Inc.; Integra LifeScience... 
Via Newswire.com
Topics Death
Illumina Celebrates International Biodiversity Day
SOURCE: Illumina 
Via 3BL Media
Topics Climate Change
Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
From Illumina, Inc.
Via Business Wire
These 7 Medical Stocks Are Breaking Down — The Sell Rule You Should Know
Former high-flyers Dexcom and Tandem Diabetes are among seven health care stocks breaking down right now, according to MarketSmith.com. 
Via Investor's Business Daily
Immuno Oncology Assays Market Worth $7.9 Billion by 2026 - Exclusive Report by MarketsandMarkets™
The global immuno-oncology assays market is projected to reach $7.9 billion by 2026. Cancer cell-based assays market report provides crucial industry insights that will help your business grow. 
Via SBWire
Tumor Genomics Market Share, Industry Growth, Trend, Statistics, Drivers, Demand, Key Companies by 2028
Increasing number of cancer cases, rising government initiatives and projects, new drug developments, and increasing demand for cancer-specific diagnostics are factors driving global tumor genomic... 
Via SBWire
DNA Sequencing in Drug Discovery Market Worth Observing Growth: Sigma-Aldrich, Siemens Healthcare Diagnostics, Promega
The DNA Sequencing In Drug Discovery Market research study presents insights into the changing competitive landscape and offers clients an accurate picture of the future direction of this industry. (To... 
Via SBWire
Topics Regulatory Compliance
Tesla, Nio Significantly Cut From Baillie Gifford Portfolio, Here's What The Firm Bought Instead In Q1
Investment management firm Baillie Gifford shed significant stake in electric carmakers Tesla Inc (NASDAQ: 
Via Benzinga
Forensic Equipment and Supplies Market Trends, Analysis, Demand and Global Industry Research Report, Region, and Segment Forecasts, 2021-2028
The growing significance of DNA analysis in criminal investigations and the rising number of forensic laboratories are the key factors fueling the growth of this market 
Via SBWire
Topics Supply Chain
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.